Incorporando los inhibidores de CDK 4/6 a la práctica Clínica habitual

PALOMA3

1,2

MONARCH2

Endocrine resistance CDK inhibitors Study Designs

Turner NC, et al. N Engl J Med 2015;

Cristofanilli M, et al. Lancet Oncol 2016;

Sledge G, et al. J Clin Oncol 2017

HR (95% CI): 0.46 (0.36, 0.59)

p=<0.0001

HR (95% CI): 0.55 (0.45, 0.68)

p=<0.001